Enanta Pharmaceuticals (ENTA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Enanta Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$14.08+0.06(<0.01%)Market closed

Market Cap

$369.44M

P/S

5.7x

P/B

3.7x

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

How this company scores

WeakMetricSide Score: 37/100

Grade capped at D — Interest coverage below 1× (-3.6x) — earnings cannot cover interest. Strongest: Growth (13/25); weakest: Cash & Earnings Quality (7/25).

Profitability10/25

Growth13/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality7/25

Strengths

Profit converts from growthNet cash position

Grade capped at D

Interest coverage below 1× (-3.6x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 5.7x5y range 1.8x – 16.4x

Currently near its 20-quarter median.

P/B · 3.7x5y range 1.0x – 5.0x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $369.44M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $65.26M
Q. Revenue: $14.36M
TTM EBITDA: $-53.82M
TTM Op. Income: $-58.73M
Q. Op. Income: $-17.24M
TTM Net Income: $-63.23M
Q. Net Income: $-19.50M
EPS: $-0.67
Shares Out.: $29.09M

$65.26M in TTM revenue grew 0.7% YoY, reaching $14.36M last quarter. TTM EBITDA of $-53.82M and TTM operating income of $-58.73M show growth is flowing through to the bottom line. However, net income is negative at $63.23M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 1% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -111.8%
Op. Margin: -120.0%
Net Margin: -135.8%

Op. margin of -120.0% is down 16.9% YoY — costs are rising relative to revenue. Net margin at -135.8% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 5.7x
P/B Ratio: 3.7x

P/S of 5.7x and P/B of 3.7x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $296.87M
Cash: $33.42M
Long-Term Debt: N/A
Book Value: $101.07M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-9.97M
TTM Free Cash Flow: $-36.94M
FCF Margin: -56.6%
FCF / Net Income: 0.6

TTM FCF of $-36.94M on $-9.97M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 15% — a weakening trend.